Free Trial
NYSEARCA:BBC

Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News

Virtus LifeSci Biotech Clinical Trials ETF logo
$29.24
+0.45 (+1.56%)
(As of 11/4/2024 ET)

About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC)

Key Stats

Today's Range
$29.24
$29.41
50-Day Range
$26.67
$30.55
52-Week Range
$16.91
$31.99
Volume
473 shs
Average Volume
3,006 shs
Market Capitalization
$11.70 million
Assets Under Management
$11.50 million
Dividend Yield
0.30%
Net Expense Ratio
0.79%
Aggregate Rating
Moderate Buy

ETF Overview

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.

Virtus LifeSci Biotech Clinical Trials ETF Expenses

TypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.79%0.56%0.55%0.51%0.52%
Other Expenses0.00%0.33%0.49%0.58%0.53%
Total Expense0.79%0.71%0.71%0.73%0.71%
Fee Waiver0.00%-0.45%-0.52%-0.67%-0.57%
Net Expense0.79%0.61%0.61%0.58%0.59%
Receive BBC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter.

BBC ETF News Headlines

Tech ETFs on the Rise After Four Weeks in Deep Red
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Headlines

BBC ETF - Frequently Asked Questions

Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $24.45 at the beginning of 2024. Since then, BBC stock has increased by 19.6% and is now trading at $29.24.
View the best growth stocks for 2024 here
.

Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF) and General Electric (GE).

Fund Details

Issuer
Virtus
Fund Name
Virtus LifeSci Biotech Clinical Trials ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:BBC
Inception Date
12/16/2014
Fund Manager
Matthew B. Brown, Seth Kadushin
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
LifeSci Biotechnology Clinical Trials Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
122

Fund Statistics

Assets Under Management
$11.50 million
Average Daily Volume
$1,933.80
Discount/Premium
0.03%

Administrator, Advisor and Custodian

Administrator
Virtus ETF Solutions, LLC
Advisor
Virtus ETF Advisers LLC
Custodian
The Bank of New York Mellon Corporation
Distributor
ETF Distributors LLC
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
Optionable
Options Volume
1
Put Options
1
Call Options
1
Short Interest
3,400 shs

Miscellaneous

Beta
1.22
Creation Unit
50,000
Creation Fee
$500.00
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Top 10 BBC Holdings

BBC Sector Exposure

BBC Industry Exposure


This page (NYSEARCA:BBC) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners